Insight Molecular Diagnostics (IMDX) Gains from Investment Securities (2020 - 2026)

Insight Molecular Diagnostics has reported Gains from Investment Securities for 7 years, with the latest figure at -$5.9 million in Q1 2026.

• Quarterly Gains from Investment Securities fell 773.27% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$851000.0 (up 87.31% YoY) and the FY2025 annual result came in at $5.9 million, up 239.09% from the prior year.
• Gains from Investment Securities fell to -$5.9 million in Q1 2026 per IMDX's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $11.2 million in Q4 2023 and troughed at -$18.3 million in Q1 2023.
• A 5-year average of -$2.4 million and a median of -$1.0 million in 2024 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities slumped 21296.67% in 2022, then surged 1741.38% in 2024.
• Over 5 years, Gains from Investment Securities stood at -$13.9 million in 2022, then jumped by 180.69% to $11.2 million in 2023, then plunged by 222.45% to -$13.7 million in 2024, then soared by 91.86% to -$1.1 million in 2025, then tumbled by 430.76% to -$5.9 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$5.9 million, -$1.1 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.